Center for Dermatology Clinical Research, Inc.

Summary

Center for Dermatology Clinical Research, Inc. is a medical facility located in Fremont, California. This center is recognized for care of Atopic Dermatitis, Medical Device Dermatitis, Plaque Psoriasis, Skin Conditions, Acne and other specialties. Center for Dermatology Clinical Research, Inc. is involved with conducting 94 clinical trials across 70 conditions. There are 1 research doctors associated with this hospital, such as Sunil Dhawan.

Top PIs

Clinical Trials running at Center for Dermatology Clinical Research, Inc.

Atopic Dermatitis

Obesity

Psoriasis

Alopecia Areata

Chronic Urticaria

Childhood Obesity

Medical Device Dermatitis

Injection Site Itch

Eczema

Medical Device Site Urticaria

EVO756

for Eczema

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

Recruiting

0 awards

Phase 2

2 criteria

FB825

for Eczema

This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.

Recruiting

0 awards

Phase 2

5 criteria

CGB-500 Ointment

for Eczema

The goal of this clinical trial is to learn if CGB-500 works to treat atopic dermatitis in participants ages 12 and older. The goal is also to learn about the safety of CGB-500. The main questions it aims to answer are: Does CGB-500 improve atopic dermatitis by decreasing the area affected and the severity of the lesions? What medical problems do participants have when taking CGB500? Researchers will compare CGB-500 to a placebo (a look-alike substance that contains no drug) to see if CGB-500 works to treat atopic dermatitis. Participants will: Take CGB-500 or a placebo every day for 8 weeks. Visit the clinic once every 2 weeks for the first month and at the end of 8 weeks. Keep a diary of when they use the product and complete a form about their symptoms including itching.

Recruiting

0 awards

Phase 2

3 criteria